Sponsor or institution

Clinical trials and research at Chiesi Farmaceutici S.p.A.

• 18Clinical trials
• 27Countries

Newest trials

All recruiting trials (18)

• Inhaled CHF10136 safety and pharmacokinetics in healthy adults and adults with asthma

  This first-in-human study tests inhaled CHF10136 to see if it is safe and well tolerated, how it behaves in the body, and how it affects adults with asthma compared with placebo.

  Recruiting Phase 1 Chiesi Farmaceutici S.p.A. · Leeds and 2 other locations · NCT07851623

• Asthma control with a single inhaler triple therapy vs a standard inhaler in adults

  This trial tests whether a single inhaler with triple therapy (ICS/LAMA/LABA) improves asthma control compared with a standard ICS/LABA inhaler in adults whose asthma is not well controlled.

  Recruiting Phase 4 Chiesi Farmaceutici S.p.A. · Rousse · NCT07666490

• Test of CHF 5993 inhaler against CHF 1535 in Chinese adults with uncontrolled asthma on medium-dose ICS+LABA

  This trial tests if CHF 5993 delivered by a pMDI is as good as or better than the reference CHF 1535 pMDI in Chinese adults with asthma not well controlled on medium-dose inhaled steroids plus a long-acting beta-agonist.

  Recruiting at 2 sites Phase 3 Chiesi Farmaceutici S.p.A. · Beijing, Chaoyang District and 1 other locations · NCT07546981

• Find a safe, effective dose of CHF10067 (zampilimab) for people with IPF

  This study tests two different doses of CHF10067 against placebo to see if they can help people with idiopathic pulmonary fibrosis.

  Recruiting at 19 sites Phase 2 Chiesi Farmaceutici S.p.A. · Dothan, Alabama and 18 other locations · NCT07516951

• Real-world effectiveness of the extra-fine BDP/FF/GB triple inhaler in Brazilian COPD patients

  This project will test whether the extra-fine BDP/FF/GB triple inhaler (Trimbow) helps adults in Brazil with severe or very severe COPD feel better and have fewer flare-ups.

  Recruiting Chiesi Farmaceutici S.p.A. · São Paulo, São Paulo · NCT07406048

• Compare a new climate-friendly CHF5993 inhaler to standard inhalers for adults with mild to moderate asthma

  This trial will see if a CHF5993 inhaler that uses a new climate-friendly propellant works the same and is as safe as standard inhalers for adults with mild to moderate asthma.

  Recruiting at 167 sites Phase 2 Chiesi Farmaceutici S.p.A. · Buenos Aires and 166 other locations · NCT07301736

• Intranasal CHF6467 safety and absorption in healthy adults

  This will test single and repeated nasal doses of CHF6467 in healthy adults to see if they are safe and how the drug gets into the blood and the fluid around the brain.

  Recruiting Phase 1 Chiesi Farmaceutici S.p.A. · Sofia · NCT07163182

• Pegunigalsidase Alfa in Fabry Disease: Real‑World Use

  This study tests how pegunigalsidase alfa works and is tolerated in adults with Fabry disease in everyday clinical practice.

  Recruiting at 2 sites Chiesi Farmaceutici S.p.A. · Arezzo and 6 other locations · NCT07109375

• Pregnancy and postpartum outcomes after pegunigalsidase alfa exposure in women with Fabry disease

  This registry will collect information to see how pregnancies and babies do when women with Fabry disease received pegunigalsidase alfa shortly before conception, during pregnancy, or while breastfeeding.

  Recruiting at 4 sites Chiesi Farmaceutici S.p.A. · Washington D.C., District of Columbia and 4 other locations · NCT06941025

• Oleogel-S10 gel for healing skin wounds in Japanese patients with epidermolysis bullosa.

  We will try Oleogel‑S10 gel to see if it closes or shrinks wounds in Japanese children and adults with junctional or dystrophic epidermolysis bullosa.

  Recruiting at 6 sites Phase 3 Chiesi Farmaceutici S.p.A. · Fukuoka and 5 other locations · NCT06917690

• Long-term evaluation of Metreleptin for patients with partial lipodystrophy

  This study is testing if long-term daily use of Metreleptin can help people with familial partial lipodystrophy feel better and improve their health.

  Recruiting at 7 sites Phase 3 Chiesi Farmaceutici S.p.A. · Birmingham, Alabama and 6 other locations · NCT06679270

• Observational study of Elfabrio® in patients with Fabry disease

  This study is testing how safe and effective Elfabrio® is for people with Fabry disease who are currently using or planning to use this treatment.

  Recruiting at 10 sites Chiesi Farmaceutici S.p.A. · Birmingham, Alabama and 9 other locations · NCT06663358

• Assessing skin cancer risk in patients with Epidermolysis Bullosa using Filsuvez

  This study is testing if using the topical gel Filsuvez can help reduce the risk of skin cancer in patients with Epidermolysis Bullosa.

  Recruiting at 6 sites Chiesi Farmaceutici S.p.A. · Palo Alto, California and 11 other locations · NCT06423573

• Evaluating the safety and effects of PRX-102 in children and adolescents with Fabry disease

  This study is testing a new treatment called PRX-102 to see if it can safely help children and teenagers with Fabry disease feel better and improve their symptoms.

  Recruiting at 11 sites Phase 2/3 Chiesi Farmaceutici S.p.A. · Phoenix, Arizona and 11 other locations · NCT06328608

• Effects of Velmanase Alfa in Young Children with Alpha-Mannosidosis

  This study is testing how well the drug velmanase alfa works for young children under 3 with Alpha-Mannosidosis to see if it helps improve their health after a year of treatment.

  Recruiting at 2 sites Chiesi Farmaceutici S.p.A. · Miami, Florida and 1 other locations · NCT06184503

• Evaluating a new treatment for Fabry disease in Japanese patients

  This study is testing a new treatment for Fabry disease in Japanese patients to see if it can help improve their health and quality of life.

  Recruiting at 8 sites Phase 2/3 Chiesi Farmaceutici S.p.A. · Chikushino-shi, Fukuoka and 9 other locations · NCT05710692

• Assessing cardiovascular and cerebrovascular events in COPD patients using different inhalers

  This study is trying to see if using a Dry Powder Inhaler is safer than a Metered Dose Inhaler for older adults with COPD by looking at heart and brain-related health issues.

  Recruiting Chiesi Farmaceutici S.p.A. · London · NCT05652439

• Registry for patients treated with metreleptin for lipodystrophy

  This study is collecting information from patients with lipodystrophy who are being treated with metreleptin to see how well it works and what side effects it might cause in real life.

  Recruiting at 20 sites Chiesi Farmaceutici S.p.A. · Birmingham, Alabama and 27 other locations · NCT02325674

Quick answers

How many clinical trials run by Chiesi Farmaceutici S.p.A. are recruiting right now?

18, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 27 countries. The most sites are in United Kingdom (9 trials), United States (8 trials), Germany (4 trials), France (3 trials), Spain (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 3, Phase 1: 2, Phase 2: 2, Phase 2/3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →